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Abstract 1!
In the HCV envelope glycoproteins E1 and E2, which form a heterodimer, E2 is the receptor 2!
binding protein and the major target of neutralizing antibodies, whereas the function of E1 3!
remains less characterized. To investigate E1 functions, we generated a series of mutants in the 4!
conserved residues of the C-terminal region of the E1 ectodomain in the context of an infectious 5!
clone. We focused our analyses on two regions of interest. The first region is located in the 6!
middle of the E1 glycoprotein (between amino acids (aa) 270 and 291), which contains a 7!
conserved hydrophobic sequence and was proposed to constitute a putative fusion peptide. The 8!
second series of mutants was generated in the aa314-342 region, which has been shown to 9!
contain two alpha helices (α2 and α3) by NMR studies. Twenty out of the twenty-two generated 10!
mutants were either attenuated or noninfectious. Several mutations modulated the virus’s 11!
dependence on claudin-1 and the scavenger receptor BI co-receptors for entry. Most of the 12!
mutations in the putative fusion peptide region affected virus assembly. Conversely, mutations in 13!
the α-helix 315-324 residues M318, W320, D321, and M322 resulted in a complete loss of 14!
infectivity without any impact on E1E2 folding and on viral assembly. Further characterization 15!
of the W320A mutant in the HCVpp model indicated that the loss of infectivity was due to a 16!
defect in viral entry. Together, these results support a role for E1 in modulating HCV interaction 17!
with its co-receptors and in HCV assembly. They also highlight the involvement of α-helix 315-18!
324 in a late step of HCV entry. 19!
 20!
Importance: 21!
HCV is a major public health problem worldwide. The virion harbors two envelope proteins, E1 22!
and E2, which are involved at different steps of the viral life cycle. Whereas E2 has been 23!
extensively characterized, the function of E1 remains poorly defined. Here we characterized the 24!
function of the putative fusion peptide and the region containing alpha helices of the E1 25!
ectodomain, which had been previously suggested to be important for virus entry. We could 26!
confirm the importance of these regions for the virus infectivity. Interestingly, we found several 27!
residues modulating the virus’s dependence on several HCV receptors, thus highlighting the role 28!
of E1 in the interaction of the virus with cellular receptors. Whereas mutations in the putative 29!
fusion peptide affected HCV infectivity and morphogenesis, several mutations in the α2 helix 30!
!4!
region led to a loss of infectivity with no effect on assembly, indicating a role of this region in 1!
virus entry.  2!
 3!
Introduction 4!
With 70 million people infected worldwide, Hepatitis C virus infection is a major health problem 5!
(1). With a high propensity for establishing chronic infections, HCV is considered as the major 6!
cause of chronic hepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The development of 7!
direct-acting antivirals (DAA) against HCV has been a milestone in the treatment of Hepatitis C. 8!
This treatment shows high efficacy against all HCV genotypes, reaching high HCV clearance 9!
rates. However, the high cost of these antiviral therapies precludes their accessibility to the large 10!
majority of HCV infected patients (2). In this context, the development of a preventive HCV 11!
vaccine would constitute the most cost-effective means to limit HCV spread. Therefore, a 12!
thorough understanding of the contribution of HCV glycoproteins E1 and E2 to viral entry and 13!
assembly is still required for the development of therapeutic and preventive vaccines.  14!
HCV is an enveloped virus with a positive stranded RNA genome that belongs to the 15!
Hepacivirus genus of the Flaviviridae family (3). Its genome encodes a single polyprotein that is 16!
processed by cellular and viral proteases into 10 polypeptides, which include seven non-17!
structural proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) and three structural proteins 18!
(the core and the two envelope glycoproteins E1 and E2) that are the components of the viral 19!
particle (4). Thus, the viral particle is composed of a nucleocapsid constituted of the genomic 20!
RNA and the core protein, which is surrounded by a lipid membrane in which the heterodimer 21!
formed by the two envelope glycoproteins E1 and E2 is anchored. E1 and E2 glycoproteins are 22!
type I transmembrane proteins with well conserved C-terminal transmembrane domains and 23!
highly glycosylated N-terminal ectodomains (5). As components of the viral particle, E1 and E2 24!
are involved in virion morphogenesis and constitute the major viral determinant of HCV entry 25!
(6) ((7). HCV entry into hepatocytes is a complex process that involves several cell surface 26!
molecules. Among them, the contributions to HCV entry of the scavenger receptor BI (SR-BI), 27!
the tetraspanin CD81, and the tight-junction proteins claudin-1 (CLDN1) and occludin (OCLN) 28!
have been the most characterized (8). 29!
!5!
For a long time, E2 was the most studied HCV envelope protein. Indeed, E2 is the major target 1!
of neutralizing antibodies, it mediates the interaction between the virus and SR-BI and CD81 2!
receptors, and it was postulated to be the fusion protein of the virus (9).  However, the structure 3!
of E2 does not harbor the features of a fusion protein, which led to the hypothesis that the fusion 4!
step would rather rely on E1 (10) (11). Recently, the N-terminal part of E1 (residues 192 to 270) 5!
was crystallized. The characterization of the role of the conserved residues of this region during 6!
the HCV life cycle showed that it is important for the virus infectivity and E1E2 heterodimer 7!
formation (12). Moreover, this region was shown to contain residues that mediate the 8!
dependence of the virus on the claudin-1 receptor for entry. In addition, a cross-talk between 9!
HCV glycoprotein E1 and the viral genomic RNA was identified (12).  10!
To further characterize the contribution of E1 to the different steps of the HCV life cycle, we 11!
generated a new series of mutants in the conserved residues of the C-terminal region of the E1 12!
ectodomain. We focused our analysis on two regions of interest. The first region is located in the 13!
middle of the polypeptide (Putative Fusion Peptide (PFP), between aa270 and 291), which 14!
contains conserved hydrophobic sequences that could potentially act as a fusion peptide (13, 14). 15!
The second series of mutants was generated in the aa314-342 region, which has been shown to 16!
contain two alpha helices (α2 and α3) by NMR and X-ray crystallography studies (15) (16). We 17!
thus took advantage of these data to further investigate the functional role of the C-terminal part 18!
of the E1 ectodomain by alanine replacement of residues in the context of an infectious clone. 19!
Out of the 22 generated mutants, only two exhibited a wild-type phenotype, while nine were no 20!
longer infectious. Several mutations modulated the dependence of the virus on claudin-1 and/or 21!
SR-BI receptors for entry. Importantly, mutations in the α2 residues M318, W320, D321, and 22!
M322 resulted in a complete loss of infectivity without any impact on E1E2 folding or on viral 23!
assembly. Further characterization of the W320A mutant in the context of the HCVpp system 24!
indicated that the loss of infectivity is due to a defect in viral entry. 25!
 26!
 27!
Results 28!
 29!
!6!
Amino acid conservation in the second half of the E1 ectodomain and mutated residues  1!
Amino acid conservation in E1 region 270 to 350 among HCV genotypes is represented on 2!
figure 1. This region contains the putative fusion peptide aa270-291 (PFP) (13) and two alpha 3!
helices α2 (aa315-324) and α3 (aa331-338) as revealed by NMR and X-ray crystallography 4!
studies performed on the aa314-342 and aa314-324 E1 peptides (15). The less variable residues 5!
of this region among HCV genotypes were individually replaced by alanine in the context of the 6!
JFH1 infectious clone. This led to the generation of 22 mutants. Among them, 5 belong to the 7!
PFP region, whereas 8 are located in the α2 helix region. Unexpectedly, the residues of the α3 8!
helix were more variable, which suggested a less important role for this region in the HCV life 9!
cycle. Mutations were introduced in a modified version of the plasmid encoding the full-length 10!
JFH1 genome in which the N-terminal E1 sequence has been modified to reconstitute the A4 11!
epitope, which is present in E1 of genotype 1a (17), and therefore allows for the identification of 12!
this modified E1 of genotype 2a for which there is no antibody readily available. It is worth 13!
noting that introduction of the A4 epitope does not affect HCV infectivity, and thus does not 14!
interfere with the characterization of the phenotypes of E1 mutants. 15!
 16!
Effect of E1 mutations on HCV replication  17!
In a first step, we assessed the ability of the produced mutants to replicate. For this purpose, the 18!
expression of several HCV proteins (E1, E2, and NS5A) was examined at 48 hours post-19!
electroporation of Huh-7 hepatoma cells with wild-type (wt) and mutant HCV RNA. For all 20!
mutants, similar levels of protein expression could be observed; hence, any effect of the 21!
mutations on viral replication could be excluded (figure 2). We included in our analysis the GND 22!
non-replicative HCV mutant and the ΔE1E2 assembly-deficient mutant that carries an in-frame 23!
deletion in E1E2 coding region. Interestingly, D279 and Q289 mutations in the PFP and Q302 in 24!
the region between PFP and α2 led to the detection of an additional band of lower molecular 25!
weight, which likely corresponds to an alternaternative glycoform of E1 as previously observed 26!
when E1 is expressed as a recombinant protein (18). 27!
 28!
Effect of E1 mutations on HCV infectivity 29!
Since the introduced mutations did not affect viral replication, we assessed their impact on the 30!
production of infectious virus. To do so, we determined the intracellular and extracellular 31!
!7!
infectivity after electroporation of Huh-7 cells with viral RNAs. We observed different 1!
phenotypes of virus infectivity: (i) complete loss of infectivity for mutants G278A, D279A, 2!
G282A, Q302A, Y309A, M318A, W320A, D321A, and M322A; (ii) severe attenuation of 3!
infectivity for G311A, T314A, G315A, H316A, R339A, and P341A; (iii) slight attenuation of 4!
infectivity for L286A, E303A, M323A, W326A, and P328A; (iv) no effect on infectivity for 5!
Q289A, R317A.  6!
In most cases, intra- and extra-cellular infectivity profiles were similar, suggesting that the 7!
mutations did not affect infectious virus release. However, the P341A mutant showed a 3-log 8!
decrease in its extracellular infectivity level compared to wild type infectivity, while its 9!
intracellular infectivity was reduced by only one log at 96 hours post electroporation. This result 10!
is in favor of an effect of this mutation on the secretion of infectious virus.  11!
These initial data show that most mutations in the putative fusion peptide and α2 helix regions 12!
result in a loss of infectivity or a severe attenuation, suggesting that these regions are important 13!
for the HCV life cycle (figure 3). 14!
 15!
Effect of E1 mutations on virion release 16!
To determine whether the mutations affected the release of viral particles, intra- and extra-17!
cellular levels of HCV core protein at 48h post-electroporation were quantified. For all mutants, 18!
the level of intracellular core protein was similar to the wild type virus, confirming the absence 19!
of effect of E1 mutations on viral replication. By contrast, the levels of extracellular core 20!
proteins were reduced for most mutants in the potential fusion peptide region that presented 21!
impaired infectivity, as well as for the severely attenuated P341A mutant, indicating a defect in 22!
the secretion or assembly of viral particles (figure 4). Interestingly, most of the mutations in or 23!
close to the E1 α2 helix (G311A, T314A, G315A, H316A, M318A, W320A, D321A, and 24!
M322A) affecting virus infectivity had no impact on the secretion of core protein, suggesting 25!
that these mutations led to the release of non-infectious viral particles.  26!
 27!
Effect of E1 mutations on HCV glycoprotein folding and E1E2 heterodimerization 28!
Since E1 and E2 cooperate for their respective folding, we analyzed the effect of the mutations 29!
on the formation of E1E2 heterodimers (19). For this purpose, we performed pulldown assays 30!
using the CD81 large extracellular loop (CD81-LEL), which recognizes correctly folded E2 31!
!8!
(figure 5A). E2 protein from all mutants could be precipitated by CD81-LEL, indicating that the 1!
E1 mutations had no effect on E2 folding. In the PFP segment and the downstream E1 region 2!
(aa274-309), nearly all mutations impacting infectivity affected the coprecipitation of E1. Thus, 3!
for the attenuated mutants (L286A, E303A), a lower signal on the E1 western blot was observed 4!
after CD81-LEL pull down. For the non-infectious mutants (G278A, D279A, Q302A and 5!
Y309A), the E1 protein was not detectable. The impairment in E1 coprecipitation indicates that 6!
these mutations affect the interaction between E1 and E2, at least in the context of properly 7!
folded E2. These results suggest that the potential fusion peptide and the downstream E1 region 8!
(aa274-309) are involved in E1E2 interaction. Thus, the loss of infectivity of the mutants in this 9!
region might be due to the associated alteration in protein folding. 10!
The G282A mutation in the PFP and the majority of the mutations in α2 and the downstream 11!
region (aa325-341) of E1 had no impact on the formation of the E1E2 heterodimer since E1 12!
could be efficiently precipitated with E2 in CD81-LEL pull down for all mutants, except for one 13!
(H316A) in this region. Thus, mutations G311A, T314A, G315A, M318A, W320A, D321A, 14!
M322A, M323A, W326A, P328A, R339A, and P341A, which led to the production of attenuated 15!
or non-infectious virus, had no impact on E1E2 interaction. These mutants do not present 16!
conformational or heterodimerization defects that could explain their loss of infectivity. 17!
To further characterize the effect of E1 mutations on the folding of the E1E2 heterodimer, we 18!
performed immunoprecipitation experiments with conformation-sensitive antibodies. In a first 19!
step, we used the human mAb AR5A, which recognizes an epitope shared by E1 and E2 (20) 20!
(figure 5A). Data obtained in this assay correlated with the results of the CD81 pull-down assay. 21!
Indeed, for the non-infectious or attenuated mutants in the potential fusion peptide and 22!
downstream region (G278A, D279A, Q302A, E303A, Y309A), E1E2 glycoproteins were either 23!
weakly or not recognized by mAb AR5A. These findings confirm that these mutations affected 24!
E1E2 conformation and that the loss of infectivity or attenuation was due to alteration in protein 25!
folding. Unexpectedly, E1 and E2 were well recognized by the AR5A mAb for the mutant 26!
L286A, for which CD81 pull-down assay showed a weak signal for E1 coprecipitation, 27!
suggesting an effect on the interaction between E1 and E2. This might be due to a partial 28!
alteration of the affinity between E1 and E2, which is in agreement with its attenuated 29!
infectivity. 30!
!9!
In the case of the G282A mutant in the PFP region and most of the mutants in the α2 and 1!
downstream region (G311A, T314A, G315A, M318A, W320A, D321A, M322A, M323A, 2!
W326A, P328A, R339A, and P341A), which are either attenuated or non-infectious, E1 and E2 3!
were recognized by AR5A mAb, excluding any effect on the heterodimerization or folding for 4!
these mutations. The absence of effects on E1E2 heterodimerization and folding is in agreement 5!
with the unimpaired virus secretion observed for the mutants in the α2 helix and downstream 6!
region. Altogether, these results suggest that these mutations lead to the production of non-7!
infectious viral particles.  8!
For the mutants in the PFP region, E1 folding was further characterized by immunoprecipitation 9!
with the E1-specific antibody IGH-526 (figure 5B), which recognizes a discontinuous epitope 10!
that includes a linear region spanning residues 313-327 (16). Due to the overlap between α2 11!
helix residues and the IGH-526 epitope, we could not use this antibody to characterize E1 12!
folding for α2 helix mutants. For all tested mutants except for the mutant Q302A, the 13!
glycoprotein E1 was recognized by the mAb IGH-526, indicating that these mutations have no 14!
drastic effect on the conformation of the E1 glycoprotein. E2 coprecipitated with E1 for most 15!
mutants. However, the signal for E2 was lower for G278A, D279A, Q302A, and Y309A mutants 16!
compared to the wild type, which is in agreement with the defect in the heterodimerization of the 17!
envelope proteins observed in the CD81 pull-down assay and AR5A immunoprecipitation. 18!
Additionally, this test further confirms a remaining interaction between E1 and E2 of the mutant 19!
L286A, which might be responsible for the attenuated infection observed for this mutant. 20!
Whereas the defects in infectivity of most PFP and aa292-309 downstream region mutants can be 21!
attributed to impairment in virus assembly and envelope protein folding, the loss of infectivity of 22!
most mutants in the α2 helix and downstream region remains unexplained. 23!
 24!
Effect of E1 mutations on HCV neutralization and inhibition by CD81 25!
During their incorporation at the surface of viral particles, envelope glycoproteins undergo 26!
structural changes (19)(21). However, due to the low particle production yield of the HCV cell 27!
culture system, biochemical analysis of particle-associated envelope proteins are difficult to 28!
implement. Alternatively, the effect of the mutations on the folding of virus-associated envelope 29!
proteins can be determined by the analysis of the sensitivity of the virus to neutralization with the 30!
help of conformational neutralizing antibodies or CD81-LEL. However, this approach is only 31!
!10!
possible for the characterization of attenuated viruses. Thus, neutralization assays were 1!
performed with mutants showing a decrease in infectivity of one log10 or less (L286A, E303A, 2!
M323A, W326A, P328A, R339A) (figure 6).  3!
The L286A and E303A mutants did not show any difference in sensitivity to inhibition by 4!
CD81-LEL and AR5A. This result contrasts with the effect of the L286A and E303A mutations 5!
on the heterodimer formation observed in biochemical interactions assays.  Thus, although these 6!
mutations affect intracellular envelope protein heterodimerization, they have no major impact on 7!
E1E2 folding at the surface of the viral particles.  8!
Conversely, α2 region mutations that had no impact on intracellular E1E2 recognition by AR5A 9!
or CD81-LEL led to an increase in virus sensitivity to inhibition by AR5A. Thus, the M323A, 10!
W326A, P328A, and R339A mutations likely induce a conformational change of virion-11!
associated E1E2, leading to a better access of the AR5A epitope.  12!
To further confirm the results obtained with AR5A, we used AR4A mAb, that recognizes a 13!
discontinuous epitope on E1 and E2, in neutralization and immunoprecipitation assays (20). As 14!
shown on figure 6D, AR4A mAb could precipitate E1 and E2 from M323A, W326A, P328A and 15!
R339A mutants with the same efficiency as wt E1E2. As found in the case of AR5A-mediated 16!
neutralization, AR4A inhibited the infectivity of M323A, P328A, W326A and R339A mutants 17!
with a higher efficiency (figure 6C). This result further supports a specific impact of these 18!
mutations on the virus-associated E1E2 conformation.  19!
On another hand, the recognition of E1E2 of E303A mutant by AR4A in immunoprecipitation 20!
assays was slightly affected, while L286A mutation had no impact on E1E2 recognition (figure 21!
6D). This confirms the effect of the E303A mutation on the conformation of intracellular E1E2 22!
glycoproteins as shown by the results obtained in AR5A immunoprecipitation. As observed in 23!
AR5A neutralization experiments, E303A and L286A do not significantly affect the 24!
neutralization efficiency of AR4A (figure 6C). These findings support a specific impact of 25!
E303A mutation on intracellular forms of E1E2 glycoproteins. 26!
 27!
Effect of E1 mutations on the recognition of HCV receptors 28!
We further characterized the phenotypes of attenuated mutants by analyzing their dependence on 29!
the main known HCV receptors. For this, we determined their sensitivity to inhibition by anti-30!
receptor mAbs, previously reported to affect HCV entry (figure 7).  31!
!11!
No significant difference in sensitivity to inhibition by the anti-CD81 antibody was observed for 1!
the mutants. The absence of effect of the mutations on the dependence on CD81 for entry was 2!
confirmed by silencing the expression of CD81 with siRNA. 3!
Interestingly, mutants in the α2 helix or downstream region (M323A, W326A, P328A, R339A) 4!
were less sensitive to inhibition by the SR-BI specific antibody, whereas the sensitivity to the 5!
SR-BI antibody was not affected for L286A and E303A mutants. Moreover, for the W326A and 6!
P328A mutants, infection was significantly less inhibited by the downregulation of SR-BI 7!
expression with siRNA. This suggests that residues M323, W326, P328, and R339 modulate 8!
HCV dependence on the SR-BI receptor.  9!
Similar phenotypes were obtained regarding CLDN1 dependence for mutants in the PFP and α2 10!
helix regions. Indeed, L286A (PFP), E303A (PFP downstream region), M323A (α2 helix), and 11!
P328A (α2 helix downstream region) were more sensitive to inhibition by the anti-CLDN1 mAb 12!
than the wild type, suggesting that they are more dependent on CLDN1 for entry. However, the 13!
W326A and R339A mutants showed the same sensitivity as the wild-type virus to anti-CLDN1 14!
inhibition, suggesting that only specific residues in the α2 helix and downstream region modulate 15!
the dependence of the virus on CLDN1. 16!
Due to the absence of an anti-OCLN mAb capable of neutralizing HCV infection, the 17!
dependence on the OCLN receptor was tested using a knock out cell line (OKH4) (22). As found 18!
for the wild-type virus, all the mutants failed to infect the cells, indicating that the mutations 19!
have no effect on the dependence on the OCLN receptor. 20!
 21!
Characterization of SR-BI independent mutants 22!
HCV associates with lipoproteins to form lipo-viro particles (LVP) (23). Moreover, HCV 23!
associated lipoproteins modulate HCV infectivity and play a role in virus interaction with SR-BI 24!
(24, 25)(26). Accordingly, E2 mutations that modulate HCV dependence on SR-BI have been 25!
associated with a shift in virion density (27) (28) (29).  In this context, we sought to determine if 26!
E1 mutations that led to a decrease in SR-BI dependence were also associated with a change in 27!
viral particle density. For this, we analyzed the density of infectious viral particles obtained for 28!
the W326A and P328A mutants. After ultracentrifugation, the distribution of infectious particles 29!
in density gradients was determined by quantification of infectivity in the different fractions. As 30!
shown in figure 8, no difference was observed between the distribution of infectious wild-type 31!
!12!
virus and mutant W326A and P328A viruses, which were mainly concentrated in the 1.05 1!
density fraction. Thus, W326A and P328A mutations that affect SR-BI dependence of the virus 2!
do not appear to affect virus association with lipoproteins.  3!
  4!
Characterization of non-infectious, assembly-competent E1 mutants  5!
In this work, we identified several mutants that either lost their infectivity (M318A, W320A, 6!
D321A, M322A) or were severely attenuated (G311A, T314A, G315A), but showed a level of 7!
core release similar to the wild type virus. Thus, these mutations did not affect viral assembly 8!
and led to the secretion of non-infectious particles. Moreover, they had no impact on E1 folding 9!
nor on E1E2 heterodimerization. Since specific mutations in E1 can induce the release of viral 10!
particles devoid of genomic RNA (12), we determined if the impaired infectivity of these 11!
mutants was due to similar defects. We chose to quantify the RNA content of the particles 12!
released for the two severely attenuated mutants, G315A in the α2 helix and G311A in the 13!
upstream region, and the non-infectious mutant W320A in the α2 helix. After electroporation of 14!
viral RNA in Huh-7 cells, viral particles released in the supernatant were precipitated with 15!
polyethylene glycol, which allowed the removal of the free RNA present in the medium after 16!
electroporation. Following this step, viral RNA was extracted and quantified by RT-qPCR. In 17!
parallel, intracellular viral RNA content was determined. As expected, lower levels of 18!
extracellular viral RNA were obtained for the non-replicative GND mutant and the assembly-19!
deficient ΔE1E2 mutant. On the opposite, viral RNA of G311A, G315A, and W320A mutants 20!
accumulated at similar levels as the wild type, both intra- and extra-cellularly (figure 9). These 21!
findings indicate that the loss of infectivity of these mutants was not due to a defect in RNA 22!
uptake in the viral particle. 23!
 24!
During morphogenesis, HCV glycoprotein E1 assembles to form non-covalent trimers which is 25!
essential for infectivity (21). Therefore, we determined the effect of the G311A, G315A, and 26!
W320A mutations on the capacity of E1 to form trimers in infected cells. Thus, after 27!
electroporation of viral RNA into Huh7 cells, envelope proteins from the lysate were 28!
concentrated by pull down with Galanthus nivalis lectin and analyzed by Western blotting 29!
without thermal denaturation as previously described (21). Similar amounts of E1 trimers could 30!
be observed for the G311A, G315A, and W320A mutants than for the wt virus, indicating that 31!
!13!
the mutations do not alter E1 trimerization (data not shown). 1!
 2!
Since they did not affect envelope protein folding, core secretion, or RNA encapsidation, the 3!
G311A, G315A and W320A mutations lead to the release of non-infectious viral particles that 4!
may be deficient in viral entry. To confirm this hypothesis, we produced retroviral particles 5!
pseudotyped with HCV envelope proteins bearing the corresponding mutations in E1. As 6!
observed in figure 10, infectivity of HCVpp carrying E1 mutations was reduced by two log 7!
compared to HCVpp wild-type infectivity. This result could be due either to a defect in particle 8!
production or to the production of non-infectious particles. We thus assessed the efficiency of the 9!
incorporation of envelope proteins in HCVpp particles. To do so, extracellular particles were 10!
concentrated on a sucrose cushion by ultracentrifugation and analyzed by Western blotting. 11!
Although similar levels of retroviral capsid proteins were observed for all viruses, lower amounts 12!
of E1 and E2 were detected for the G311A and G315A mutants, indicating that these mutations 13!
affect E1 and E2 incorporation in HCVpp viral particles. By contrast, the W320A mutation was 14!
associated with an increased incorporation of E1 and E2 in the particles, as shown by the 15!
detection of higher amounts of E1 and E2 in the concentrated particles samples. Thus, the loss of 16!
infectivity of G311A and G315A might be due to an impaired incorporation of the envelope 17!
proteins in the viral particles, while the absence of infectivity of the W320A mutant indicates an 18!
effect of this mutation on virus entry. 19!
 20!
Discussion 21!
 22!
Although the precise role of E1 in the HCV life cycle has been poorly characterized until 23!
recently, the structure of E2 suggests that E1 might play a key role in the fusion process (10, 11). 24!
Moreover, the recent characterization of the role of conserved residues in the N-terminal part of 25!
the protein highlighted a role for E1 in the virus interplay with CLDN-1 and in the incorporation 26!
of viral RNA into the nucleocapsid (12). To further characterize the role played by the E1 protein 27!
during the HCV life cycle, we investigated the functional role of the C-terminal region of the 28!
ectodomain, which contains the putative fusion peptide and two alpha helices. Our results show 29!
that several residues in the PFP and the downstream region play a role in E1E2 30!
heterodimerization, as well as in the assembly and release of infectious viral particles. Several 31!
mutations in the PFP and the α2 helix region decreased the sensitivity of the virus to 32!
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neutralization by CLDN1 or SR-BI-specific antibodies, indicating a functional role for E1 in 1!
HCV-CLDN1 and HCV-SR-BI interaction. Furthermore, most mutations in the α2 region 2!
affected virus infectivity without any effect on virion assembly, suggesting that they led to the 3!
secretion of non-infectious or attenuated viruses, likely defective in virus entry.  4!
Most mutations in the PFP region and the downstream region (G278A, D279A, L286A, Q302A, 5!
E303A, Y309A) affect the interaction between E1 and E2. These results confirm the 6!
involvement of E1 region aa290 to 306 in E1E2 interaction, as observed in the computational 7!
prediction of the E1E2 heterodimer structure proposed by Freedman (30). Thus, although 8!
interactions between E1 and E2 transmembrane domains are essential for E1E2 9!
heterodimerization, several residues in their ectodomains also contribute to the interaction. 10!
Indeed, N-terminal residues 201 to 206 are essential for the structure of the AR5A and AR4A 11!
antibody epitope, which spans the E1 and E2 proteins (20). Recently, Gopal and collaborators 12!
generated a library of alanine scanning mutants covering the full E1E2 sequence of the genotype 13!
1a H77 strain (31). Using a high throughput flow cytometry-based assay, they probed the 14!
mutants library for binding to a collection of antibodies. In agreement with our data, this 15!
approach revealed a decrease in the recognition of mutants G278A, D279A, Q302A and D303A by 16!
AR5A whereas mutants G282A, L286A, Q289A and G311A were unaffected. Moreover, the 17!
characterization of the functionality of chimeric heterodimers derived from different genotypes 18!
allowed the identification of residues at position 308, 330, and 345 as being involved in the 19!
functional interaction between E1 and E2 (32). In addition, we previously identified three 20!
residues (W239, I262, D263) located in the β-sheet structure of the N-terminus part of E1 that 21!
are involved in E1E2 interaction (12). Among the mutants in the PFP region that presented a 22!
deficiency in infectivity, only G282A was not affected in its capacity to interact with E2. 23!
However, this mutation led to an impairment in virion assembly that might explain the loss of 24!
infectivity of this mutant. It is worth noting that the functionality of this residue was 25!
characterized in the HCVpp system of genotypes 2a and 1a (33, 34), and in a cell culture model 26!
allowing the trans-complementation of E1 in the HCV genome lacking the E1-coding sequence. 27!
In these contexts, the mutation led to a severe decrease in infectivity. Furthermore, in the E1-28!
transcomplementation HCV system, lower levels of extracellular viral RNA were obtained for 29!
this mutant, which supports an effect of the mutation on virus assembly.  30!
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Several attenuated mutants in the PFP (L286A), in the downstream region (E303A), and in the 1!
α2 region (M323A, P328A) exhibited an increased sensitivity to neutralization of infectivity by 2!
CLDN1-specific antibodies, suggesting that these mutants are more dependent on CLDN1 for 3!
cellular entry. This result is in line with the potential involvement of E1 in HCV-CLDN1 4!
interplay, as previously observed (12, 35). However, E1 mutations reported until now (T213A, 5!
I262A, H316N) had an opposite effect on CLDN1 dependence, since they led to a decreased 6!
sensitivity of the virus to the inhibitory effect of anti-CLDN1 antibodies while increasing its 7!
dependence on CLDN6 for entry. Thus, it seems that different regions of E1 have opposite 8!
effects on the requirement of CLDN1 for HCV entry. Moreover, these results strengthen the 9!
hypothesis of the involvement of E1 in HCV particle interaction with the CLDN1 coreceptor. 10!
Whereas some E1 mutations have been shown to affect the binding of HCVpp to CLDN1-11!
expressing cells, no direct interaction between E1 and CLDN1 has been reported until now. 12!
Alternatively, E1 could modulate the affinity of E2 for CLDN1 as it was reported for the E2-13!
CD81 interaction (12, 19). 14!
Several mutations in the α2 region (M323A, W326A, P328A) affect the dependence of HCV on 15!
SR-BI for entry. Indeed, these mutants were found to be partially resistant to inhibition of the 16!
infection by an SR-BI-specific antibody or by siRNA treatment. Several mutations in E2 17!
(G451R, V514A, and the murine CD81-adapted HCV mutant Jc1/mCD81), as well as the 18!
deletion of HVR1 have been previously shown to decrease the dependence of the virus on SR-BI 19!
(27) (7, 28). At the same time, these variants exhibited an increased affinity for CD81. In 20!
contrast, the M323A, W326A, and P328A E1 mutants had no significant effect on the 21!
dependence of the virus on CD81, but M323A and P328A presented an increased dependence on 22!
CLDN1. Therefore, it seems that the alteration of the interaction between the envelope proteins 23!
and a receptor frequently impacts their affinity for other entry receptors. These findings are in 24!
agreement with the finely regulated process of HCV entry that sequentially involves SR-BI, 25!
CD81, CLDN1, and OCLN (reviewed in (32)). SR-BI plays a role at several steps of the entry 26!
process (27, 36). It is notably thought to contribute to virus attachment through interaction with 27!
virus-associated lipoproteins. Its lipid transfer activity has been also shown to be important for 28!
productive viral entry. In agreement with the functional interaction of SR-BI with HCV-29!
associated lipoproteins, several E2 mutations that reduce SR-BI dependence were found to be 30!
associated with an increase in viral particle density (27). This density shift is supposed to reflect 31!
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a change in the lipid content of HCV particles and has been suggested to explain the lower 1!
dependence of this mutant on SR-BI for entry. Interestingly, cysteine mutations in E1 (C207A 2!
and C272A) have also been shown to affect the density of infectious viral particles, suggesting 3!
that the E1E2 heterodimer influences the interplay between HCV and lipoproteins. In line with 4!
this result, E1 and E2 have been shown to interact with ApoE, whose expression is essential to 5!
the production of infectious viral particles (37–39). In the case of the W326A and P328A 6!
mutants, no change in the density of the particle could be observed, which suggests that other 7!
parameters might influence the interaction of the virus with SR-BI. Alternatively, E1 mutations 8!
might modulate the interaction of E2 with SR-BI, as previously reported for its interaction with 9!
CD81 (19).  10!
Most mutations in the α2 helix region of E1 led to a severe decrease or a loss of infectivity 11!
without affecting E1E2 heterodimerization nor the viral particle assembly. It is worth noting that 12!
the absence of effect of most mutations in α2 helix region on E1E2 conformation had been 13!
previously observed in the characterization of the binding of E1E2-specific antibodies to an 14!
alanine scanning E1E2 mutants library (31). Further characterization of the attenuated mutants 15!
(M323A, W326A, P328A) revealed a change in their dependence on CLDN1 and SR-BI for 16!
entry. These results suggest that the E1 α2 helix region is important for the interplay of HCV 17!
with SR-BI and CLDN1 receptors during the entry process. For the severely attenuated mutants 18!
G311A and G315A, we observed a deficiency in the incorporation of the envelope proteins in the 19!
HCVpp model that could explain the effect of these mutations on infectivity. Due to the 20!
difficulties of producing non-infectious HCVcc particles in great amounts, we could not 21!
determine the level of E1E2 incorporation in HCVcc particles for these mutants. On the opposite, 22!
the characterization of the non-infectious W320A mutant did not reveal any deficiency that could 23!
explain its loss of infectivity. Indeed, this mutation had no effect on E1E2 heterodimerization, 24!
particle assembly, E1 trimerization, or viral RNA encapsidation. These results and the absence of 25!
infectivity observed for this mutant in the HCVpp system support an effect of the mutation on 26!
the virus’s entry step. Unfortunately, our attempts to further determine the step of entry that was 27!
impaired were unsuccessful due to the low production of particles. Finally, our data would be in 28!
agreement with the direct or indirect involvement of the α2 region in the fusion step of the entry, 29!
as suggested by the membranotropic properties of this region (15).  30!
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Interestingly, the functional characterization of IGH526 epitope (16) revealed that, similarly to 1!
what we found in HCVcc, G315A, M318A, D321A and M322A mutations dramatically affected 2!
the infectivity of genotype 1a HCVpp. However, introduction of W320A mutation in HCVpp of 3!
genotype 1a only resulted in a 30% decrease of infectivity. The more pronounced decrease of 4!
infectivity observed for this mutant in HCVcc and HCVpp 2a could be due to the difference of 5!
sequences between genotypes 1a and 2a envelope proteins that may modulate the functional 6!
impact of the mutations. The potential involvement of α2 helix region in fusion would suggest 7!
that IGH526 inhibits HCV infection by targeting the fusion step as it has been reported for some 8!
HIV and influenza viruses neutralizing antibodies (16, 40). 9!
On the other hand, our data revealed that the PFP region is important for E1 and E2 interaction, 10!
as well as for virus assembly, which does not exclude an involvement of this region in the fusion 11!
step between the viral and cell membrane. Indeed, while mutations in the fusion peptide of the 12!
viral fusion protein lead to a loss of activity and a consequent loss of virus entry, they can also 13!
affect additional steps of the viral life cycle. For instance, mutations in the fusion peptide of the 14!
Semliki Forest virus have been shown to affect the interaction between the two envelope 15!
proteins, as well as the assembly of the virus (41, 42). In addition, mutation of one glycine 16!
residue in the fusion peptide of the influenza virus can result in a variety of phenotypes, 17!
depending on the nature of the substituted residue (43). However, the fact that mutations in the 18!
PFP region affect different steps of the HCV life cycle complicates the characterization of the 19!
role of this region in the entry and fusion steps. Thus, in addition to the potential involvement of 20!
PFP in fusion suggested in previous studies (13, 14), our results suggest that the E1 α2 helix also 21!
participates in this entry step. The contribution of several E1 regions to fusion is in line with the 22!
fact that fusion is a complex process that involves several membranotopic segments of the 23!
envelope proteins. While the fusion peptide is responsible for the first step of fusion, additional 24!
envelope proteins segments have been shown to be involved at later stages of fusion, such as 25!
pore formation or enlargement (44–46). As found for other enveloped viruses, the resolution of 26!
the E1 crystal structure would provide crucial elements to definitively identify the fusion peptide 27!
of HCV. 28!
To conclude, our results exemplify the important roles played by E1 at different stages of the 29!
HCV life cycle, including involvement in E1E2 assembly, in virus morphogenesis, in the 30!
interplay with HCV receptors, and potentially in the fusion step.  31!
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 1!
MATERIALS AND METHODS 2!
Cell culture. Huh-7 human hepatoma cells (47) were grown in Dulbecco’s modified essential 3!
medium (ThermoFisher), supplemented with GlutaMAX, 10% fetal calf serum and nonessential 4!
amino acids. 5!
Antibodies. Anti-HCV monoclonal antibodies (mAbs) A4 (anti-E1) (48) and 3/11 (anti-E2; 6!
kindly provided by J. A. McKeating, University of Birmingham, Birmingham, United 7!
Kingdom)(49) were generated in vitro by using a MiniPerm apparatus (Heraeus) as 8!
recommended by the manufacturer. Anti-E1E2 mAbs AR4A and AR5A (20) and anti-E1 mAb 9!
IGH526 (16) were kindly provided by M. Law (Scripps Research Institute, La Jolla, CA, USA). 10!
The anti-NS5A mAb 9E10 (50) was a gift from C. M. Rice (Rockefeller University, New York, 11!
NY, USA) and a polyclonal antibody raised against NS5A (51) was kindly provided by M. 12!
Harris (University of Leeds, United Kingdom). The mAb A6 (anti-E1) has been previously 13!
described (52). Anti-CLDN1 mAb OM8A9-A3 has been described before (53). Anti-CD81 mAb 14!
JS81 (BD Pharmingen), anti-SR-BI mAb Cla-I (BD Biosciences) and anti-tubulin (Sigma) are 15!
commercially available, as well as the secondary antibodies used for immunofluorescence, which 16!
were purchased from Jackson ImmunoResearch. Anti-capsid of murine leukemia virus (MLV, 17!
ATCC CRL1912) was produced in vitro by using a MiniPerm apparatus (Heraeus) as 18!
recommended by the manufacturer. 19!
Mutagenesis and virus production. The virus used in this work is a modified version of the 20!
JFH1 isolate (genotype 2a; GenBank accession number AB237837) (54), kindly provided by T. 21!
Wakita (National Institute of Infectious Diseases, Tokyo, Japan). It was engineered to 22!
reconstitute the A4 epitope in E1 (pJFH1-CS-A4) (17) and titer-enhancing mutations (55).  23!
Mutants were generated by site-directed mutagenesis and the selected conserved residues were 24!
replaced by alanine. Viral RNAs were produced by in vitro transcription as previously reported 25!
(56). Viruses were produced by electroporation of viral RNA into Huh7 cells as previously 26!
described (12). The controls used in this study are the GND mutant, a non-replicative control of 27!
the HCV genome containing a GND mutation in the NS5B active site (54) and the ΔE1E2 28!
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mutant, an assembly deficient control, which contains an in-frame deletion introduced into the 1!
E1E2 regions (54). 2!
Infectivity assays. Intra- and extra-cellular infectivities were determined as described (56). In 3!
brief, viral RNAs were electroporated into Huh-7 cells. Supernatants containing extracellular 4!
virus were collected at different time points (48, 72, 96h) after electroporation, and cell debris 5!
was eliminated by centrifugation for 5 min at 10,000 g. To obtain intracellular viral particles, 6!
infected cells were washed with phosphate-buffered saline (PBS) and harvested after 7!
trypsinization, which was then followed by four freeze-thaw cycles. Cell lysates were then 8!
clarified by centrifugation at 10,000 g for 7 min. The clarified supernatants containing 9!
extracellular virus or intracellular virus were used for infection of naive Huh-7 cells. Infected 10!
cells were later fixed with ice-cold methanol (100%) and immunostained with A4 anti-E1 11!
antibody.  12!
Immunofluorescence. Immunofluorescence analyses were performed as previously described 13!
(57). Briefly, after fixation of Huh-7 infected cells with cold methanol (100%) for 10 min, cells 14!
were washed twice with PBS and incubated in 10% goat serum for 10 min. The primary anti-E1 15!
antibody A4 was diluted in 10% goat serum and the cover slips were incubated with the antibody 16!
for 25 min at room temperature. The cells were then washed three times with PBS. The 17!
secondary Cy3-conjugated antibody diluted in goat serum (1/500) was incubated with the cells 18!
for 20 min. The cells were washed again with PBS. Nuclei were stained with DAPI (4’,6-19!
diamidino-2-phenylindole). Images were processed using ImageJ software.  20!
Equilibrium density gradient analysis. Equilibrium density gradient analyses were performed 21!
as described (19) after polyethylene glycol (PEG) precipitation of viral preparations (58). 22!
Briefly, supernatants were collected at 48h following electroporation of Huh7 cells. 23!
Approximately 80 ml of viral supernatant were precipitated using PEG 6000 at a final 24!
concentration of 8%. The mixture was incubated overnight at 4°C, centrifuged for 25 min at 25!
8,000 rpm (Beckman JLA-10.5 rotor), and the pellet was resuspended in 1 ml sterile PBS. Then 26!
the concentrated viral solution was loaded on a 10 to 50% continuous iodixanol gradient. The 27!
gradients were spun for 16h at 36,000 rpm in a SW41 rotor (Beckman). Fractions of 1 ml were 28!
collected from the top of each tube and analyzed for their infectivity and density. 29!
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HCV core protein quantification. HCV core protein was quantified by a fully automated 1!
chemiluminescent microparticle immunoassay according to the manufacturer’s instructions 2!
(Architect HCVAg; Abbott, Germany)(59). 3!
Western blotting. Western blotting experiments were performed as previously described (12). 4!
Cells were lysed in PBS lysis buffer (1% Triton X-100, protease inhibitor cocktail [Roche]). Cell 5!
lysates were then precleared by centrifugation at 14,000 g for 10 min at 4°C. Protein samples 6!
were heated for 7 min at 70°C in Laemmli sample buffer, followed by separation by SDS-PAGE. 7!
The proteins were then transferred onto nitrocellulose membranes (Hybond-ECL; Amersham) 8!
and detected with specific primary antibodies, which was followed by incubation with the 9!
corresponding peroxidase-conjugated anti-rat (Jackson), anti-sheep (Amersham), anti-human or 10!
anti-mouse (Dako) antibodies. Detection of proteins was done using enhanced 11!
chemiluminescence (ECL) (Amersham) as recommended by the manufacturer. 12!
CD81 interaction and immunoprecipitation assays. CD81 pulldown and immunoprecipitation 13!
experiments were performed as previously described (7). Cells were lysed in lysis buffer (1% 14!
Triton X-100, protease inhibitor cocktail (Roche) in PBS). Cell lysates were then cleared by 15!
centrifugation at 14,000 g for 15 min at 4°C. For CD81 pulldown, glutathione-Sepharose beads 16!
(glutathione-Sepharose 4B; Amersham Bioscience) were washed twice with cold PBS to remove 17!
the storage buffer. For each cell lysate sample, 50 µl of glutathione beads was incubated with 10 18!
µg of human CD81 (hCD81) large extracellular loop (LEL) glutathione S-transferase (GST) 19!
recombinant protein in 1 ml of cold PBS containing 1% Triton X-100 for 2h at 4°C. After 20!
incubation, glutathione-Sepharose beads were washed with cold PBS. Cell lysates containing 21!
E1E2 proteins were then incubated with the glutathione beads-CD81-LEL complex overnight at 22!
4°C. The next day, beads were washed five times with cold PBS 1% Triton X-100, then finally 23!
resuspended in 30µl of Laemmli buffer and heated at 70°C for 10 minutes.  Samples were loaded 24!
onto 10% SDS-PAGE gels and HCV envelope glycoproteins were revealed by Western blotting. 25!
For immunoprecipitation assays, 70 µl of protein A-agarose beads were incubated with 10 µg of 26!
rabbit anti-human IgG (Dako) in 1 ml of cold PBS 1% Triton X-100 for 2h at 4°C. Meanwhile, 27!
100 µl of cell lysates were incubated with 2 µg of mAb AR5A (anti-E1E2) or mAb IGH526 28!
(anti-E1) in 400 µl of cold PBS 1% Triton X-100 for 2h at 4°C. After incubation, the agarose 29!
beads were washed twice with cold PBS 1% Triton X-100 and added to cell lysates. The mixture 30!
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was incubated for 90 min at 4°C, which was followed by washing the beads five times with cold 1!
PBS 1% Triton X-100. Finally, the beads were resuspended in 30 µl of Laemmli buffer. The 2!
presence of HCV envelope glycoproteins was then detected by Western blotting. 3!
Entry inhibition assays and neutralization assays. Viruses or cells were preincubated with 4!
human CD81-LEL, mAb AR5A, or anti-receptor antibody for 2 h at 37°C. The viruses were then 5!
inoculated onto Huh-7 cells. At 6 h post-infection, the inoculum was removed, and the cells were 6!
further incubated for 72 h with complete medium. The cells were then processed for 7!
immunofluorescence to measure residual infectivity. 8!
HCVpp assay. HCVpp were produced as described previously (6). Briefly, 293T cells seeded 9!
for 1 day in 6 well plates were co-transfected with 300ng/well of a pcDNA plasmid expressing 10!
HCV envelope glycoproteins (JFH1), 300ng of a murine leukemia virus (MLV) Gag-Pol 11!
expression packaging vector, and 400ng of a Firefly luciferase reporter transfer vector. Plasmid 12!
containing no envelope protein sequence was used as a negative control. After transfection, cells 13!
were incubated for 48h at 37°C. Supernatants containing the pseudoparticles were then harvested 14!
and filtered through 0.45-µm pore-sized membranes to be used as HCVpps in infection assays or 15!
pelleted by ultracentrifugation through a 20% sucrose cushion at 27000rpm (Beckman Type SW 16!
41 rotor) for 4h at 4°C and analyzed by Western blotting. To minimize artifacts that might be 17!
caused by differences in the quality of preparations, each experiment was performed using 18!
concurrently produced pseudoparticles (60). Infectivity of HCVpp on target Huh-7 cells was 19!
assessed after 72 h by using a firefly luciferase reporter gene activity kit (Promega), as 20!
recommended by the manufacturer. Results are presented as the means ± standard deviations of 21!
results of three independent experiments.  22!
Graphs and statistics. Prism, version 5.0c (GraphPad Software, Inc., La Jolla, CA), software 23!
was used for creating graphs and to determine statistical significance of differences between data 24!
sets using a Mann-Whitney test. 25!
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Figure Legends 1!
Figure 1. E1 C-terminal region sequence analyses. (A) The E1 aa 270–350 sequence from the 2!
HCV JFH1 strain (AB047639; genotype 2a) is indicated with respect to the polyproteins 3!
numbering. Amino acids mutated in this study are indicated by a red dot. (B) Amino acid 4!
repertoires of the C-terminal region of E1. The aa repertoire was deduced from the ClustalW 5!
multiple alignment of the 28 representative E1 sequences from confirmed genotypes and 6!
subtypes in the European HCV database (listed in 7!
https://euhcvdb.ibcp.fr/euHCVdb/jsp/nomen_tab1.jsp). Amino acids observed at a given position 8!
in fewer than two distinct sequences were not included. Amino acids observed at a given position 9!
in more than 25 distinct sequences are shown in capital letters. The degree of aa conservation at 10!
each position can be inferred from the extent of variability (with the observed aa listed in 11!
decreasing order of frequency from top to bottom) together with the similarity index according to 12!
ClustalW convention (asterisk, invariant; colon, highly similar; dot, similar).  13!
 14!
Figure 2. Effect of E1 mutations on the expression of viral proteins. Viral RNA transcribed from 15!
JFH1-derived mutants was electroporated into Huh-7 cells that were lysed 48 h later. Viral 16!
proteins were separated by SDS-PAGE and revealed by Western blotting with mAbs A4 (anti-17!
E1), 3/11 (anti-E2), anti-NS5A as well as anti-beta-tubulin antibody to verify loading of equal 18!
amounts of cell lysates. The protein detected by mAb A4 in cells expressing ∆E1E2 mutant 19!
corresponds to a fusion protein between the N-terminus of E1 and the C-terminus of E2.  20!
 21!
Figure 3. Effect of mutations on extracellular and intracellular infectivities. Viral RNA 22!
transcribed from JFH1-derived mutants was electroporated into Huh-7 cells. Infectivities of the 23!
supernatants and intracellular viruses were determined at 48, 72, and 96 h post-electroporation 24!
by titration. Error bars indicate standard errors of the means from at least three independent 25!
experiments. Values were compared to the wild-type virus. Differences were considered 26!
statistically significant for extracellular infectivity of mutants G278A, D279A, G282A, L286A, 27!
Q302A, E303A Y309A, G311A, T314A, G315A, H316A, M318A, W320A, D321A, M322A, 28!
W326A, R339A, and P341A (P value < 0.05) and for intracellular infectivity of mutants G278A, 29!
!29!
D279A, G282A, L286A, Q302A, E303A Y309A, G311A, T314A, G315A, H316A, 1!
M318A,W320A, D321A, M322A, R339A, and P341A (P value < 0.05) at 96h post infection. 2!
 3!
Figure 4. Effects of E1 mutations on HCV core protein secretion. Huh-7 cells were 4!
electroporated with wild-type or mutant viral RNAs. The levels of core protein in supernatants 5!
and cell lysates were determined at 48h post-electroporation. Error bars indicate standard error of 6!
the means from at least three independent experiments. Values of core protein were compared to 7!
the wild type value. Differences were considered statistically significant for extracellular mutants 8!
G278A, D279A, G282A, L286A, Q302A, E303A Y309A, and P341A (P value <0.05). 9!
 10!
Figure 5. Effect of E1 mutations on E1E2 conformation. (A upper panel) Interaction of HCV 11!
glycoproteins and CD81 (HCV entry factor). E1 and E2 from cell lysates were analyzed by GST 12!
pulldown at 48h post-electroporation using a CD81-LEL-GST fusion protein. Pulled-down E1 13!
and E2 were separated by SDS-PAGE and revealed by Western blotting with mAbs anti-E1 (A4) 14!
and anti-E2 (3/11). (A lower panel and B) Recognition of HCV E1 and E2 glycoproteins by 15!
conformation-sensitive anti-E1E2 mAb AR5A and anti-E1 mAb IGH526, as indicated. At 48h 16!
post-electroporation, E1 and E2 proteins from cell lysates were analyzed by immunoprecipitation 17!
with mAbs AR5A and IGH526. Immunoprecipitated proteins were revealed by Western blotting 18!
using mAbs A4 and 3/11.  19!
 20!
Figure 6. Effect of E1 mutations on E1E2 interaction with HCV neutralizing antibodies and 21!
CD81. (A) CD81 inhibition assays, (B) AR5A and (C) AR4A neutralization experiments were 22!
carried out by incubating E1 mutants or wild-type virus with increasing concentrations of human 23!
CD81-LEL, mAb AR5A or mAb AR4A at 37°C for 2 h.  The mixture was then added to naïve 24!
Huh-7 cells that were plated one day before. At 72h post-infection, infectivity was determined by 25!
immunofluorescence. The values are the combined data from three independent experiments. 26!
The error bars represent standard errors of the means. Results were compared to those of the wild 27!
type and a P value of < 0.05 was obtained for mutants M323A, W326A, P328A and R339A in 28!
the AR5A and AR4A neutralization experiments. (D) Recognition of HCV E1 and E2 29!
!30!
glycoproteins by conformation-sensitive anti-E1E2 mAb AR4A. At 48h post-electroporation, E1 1!
and E2 proteins from cell lysates were analyzed by immunoprecipitation with mAb AR4A. 2!
Immunoprecipitated proteins were revealed by Western blotting using mAbs A4 and 3/11.  3!
 4!
Figure 7. Effect of E1 mutations on the recognition of HCV receptors. Huh-7 cells were 5!
preincubated at 37°C for 2 h with increasing concentrations of antibodies targeting HCV 6!
receptors: (A) anti-CD81 mAb JS81, (B) anti-CLDN1 mAb OM8A9-A3 and (C) anti-SR-BI 7!
mAb Cla-I. E1 mutants or wild-type virus were then inoculated onto the cells.  At 72 h 8!
postinfection, the residual infectivity was determined by immunofluorescence. The values are the 9!
combined data from three independent experiments. The error bars represent standard errors of 10!
the means. Results were compared to those of the wild type. A P value <0.05 was determined for 11!
mutants L286A, E303A, M323A, P328A in presence of anti-CLDN1 mAbs and for mutants 12!
M323A, W326A, P328A, and R339A in the presence of anti-SR-BI mAbs. (D) SRB1 or CD81 13!
expression was downregulated by siRNA targeting SRB1 or CD81 mRNA. Infectivity is 14!
expressed as the percentage of infection performed in the presence of the control siRNA. Mean 15!
values and standard deviations from three independent experiments are shown. The unpaired t 16!
test was used to compare the infectivities of the wild-type and mutant viruses. Differences were 17!
considered statistically significant if the P value was < 0.05. 18!
 19!
Figure 8. Density gradient analyses of SRBI independent mutants. Concentrated supernatants of 20!
cells electroporated with HCV RNA were separated by sedimentation through a 10 to 50% 21!
iodixanol gradient. Fractions were collected from the top and analyzed for their infectivity by 22!
titration and for their density.  23!
 24!
Figure 9. Effect of E1 mutations on viral RNA incorporation. Huh-7 cells were electroporated 25!
with mutants and wt RNA. At 48h post-electroporation, intracellular viral RNA was extracted 26!
and quantified by quantitative RT-PCR (A). In parallel, the viral particles were precipitated from 27!
the supernatant with polyethylene glycol and concentrated by ultracentrifugation. Extracellular 28!
!31!
viral RNA contained in the concentrated virus was extracted and quantified by quantitative RT-1!
PCR (B). 2!
 3!
Figure 10. Effect of E1 mutations on HCVpp infectivity. Infectivity of HCVpp harboring E1 4!
with G311A, G315A, or W320A mutation.  (A) HCVpp infectivity was determined by 5!
measuring the activity of the luciferase reporter gene in infected Huh7 cells. Pseudotyped 6!
particles produced in the absence of envelope proteins were used as negative controls. Results 7!
are reported as the means ± standard deviations (error bars) of three independent experiments. A 8!
P value<0.05 was obtained for mutants G311A, G315A, and W320A. (B) Effect of E1 mutations 9!
on the incorporation of envelope proteins in HCVpp particles. Cells producing HCVpp were 10!
lysed and analyzed by Western blotting. HCVpp contained in the supernatants of transfected 11!
293T cells were concentrated on a 20% sucrose cushion by ultracentrifugation and analyzed by 12!
Western blotting. E1, E2, and capsid were detected using mAbs A6, 3/11 and CRL1912, 13!
respectively. 14!
!32!
!1!
Table 1: Summary of the phenotypes of E1 mutants 2!
E1!
region!
Mutant! Infectivity(a)!
Core!
secretion(b)!
E1E2!heterodimerization!and!
folding(c)!
Infection!inhibition!assays!(d)!
CD81!PD!
IP!AR5A! IP!AR4A!
hCD81!
LEL!
AntiGE1E2!
AntiGCD81! AntiGCLDN1! AntiGSRBI!
E1! E2! AR5A! AR4A!
!!
Wild!
type!
+++! ++! ++! ++! ++! ++! ++! ++! ++! ++! ++! ++!
FP! G278A! G! G! G! ++! G! ND! ND! ND! ND! ND! ND! ND!
FP! D279A! G! G! G! ++! +! ND! ND! ND! ND! ND! ND! ND!
FP! G282A! G! G! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
FP! L286A! ++! G! +! ++! ++! ++! ++! ++! ++! ++! +++! ++!
FP! Q289A! +++! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
!! Q302A! G! G! G! ++! G! ND! ND! ND! ND! ND! ND! ND!
!! E303A! ++! G! +! ++! +! +! ++! ++! ++! ++! +++! ++!
!! Y309A! G! G! G! ++! G! ND! ND! ND! ND! ND! ND! ND!
!! G311A! +! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
!! T314A! +! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
α2! G315A! +! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
α2! H316A! +! ++! +! ++! +! ND! ND! ND! ND! ND! ND! ND!
α2! R317A! +++! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
α2! M318A! G! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
!33!
α2! W320A! G! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
α2! D321A! G! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
α2! M322A! G! ++! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
α2! M323A! ++! ++! ++! ++! ++! ++! ++! +++! +++! ++! +++! G!
!! W326A! ++! ++! ++! ++! ++! ++! ++! +++! +++! ++! ++! G!
!! P328A! +++! ++! ++! ++! ++! ++! ++! +++! +++! ++! +++! G!
!! R339A! ++! ++! ++! ++! ++! ++! +! +++! +++! ++! ++! G!
!! P341A! G! +! ++! ++! ++! ND! ND! ND! ND! ND! ND! ND!
(a)The infectivity of HCVcc harbouring the different E1E2 glycoproteins in the supernatant of electroporated Huh-7 cells was quantified 96h post 
electroporation (Fig. 3). +++: infectious titers higher than 104 ffu/mL; ++: infectious titers higher than 103 ffu/mL; +: infectious titers higher than 102 
ffu/mL; -: titer between 0 and 50 ffu/mL. 
(b)Secretion of core Ag in the supernatant quantified at 48 h post electroporation of Huh-7 cells (Fig. 4). ++, concentration greater than or equal to the 
wild type; +, concentration reduced by less than one log.; -, concentration reduced by one log. or more. 
(c) The recognition of E1E2 proteins by AR4A and AR5A conformational antibodies and their interaction with hCD81 LEL were determined by 
precipitation experiments (Fig. 5). ++, similar amount of E1E2 precipitated to that of the wild type; +, lower amount of E1E2 precipitated;  -,  no 
E1E2 precipitated. ND, not determined.  
(d) The sensitivity of the mutants to inhibition of infectivity by different antibodies or the hCD81 LEL was assessed (Fig. 6 and 7). ++, wild-type 
sensitivity to neutralization; +++, higher sensitivity to inhibition than the wild type; +, lower sensitivity to inhibition than the wild type; ND, not 
determined. 
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